Schizophrenia

Because symptoms can manifest differently in each patient, some individuals with schizophrenia have handled social isolation better than others.

A combination of medications and therapy is viewed as the most effective method of treating schizophrenia.

A physician's assistant for Oasis Lifecare discusses some of the new and promissing treatments for schizophrenia.

Patients with adolescent disruption of cognitive developed had more severe symptoms following a schizophrenia diagnosis.

Why the field lacks behind in effective diagnostic tools, which could better inform tailored therapy.

The novel target therapy has reported promising early findings. What is its potential?

How have natural-cause mortality rates changed over time in an international population?

How psychiatry can catch up to other specialties in accurate, timely diagnostics based on molecular breakthrough.

SEP-363856 is showing initial efficacy and long-term safety in adult patients.

Data regarding major adverse events remain unreliable due to a lack of a patient registry.

A public health expert shares insight on the positives and pitfalls learned from stigma-reduction campaigns.

SEP-36856 helps patients with schizophrenia manage some of the side effects commonly found in antipsychotics.

A new algorithm using a 70% training had a 51.7% success rate in predicting individualized treatments for first-episode schizophrenia patients.

Early psychosis patients experienced better social functioning after cognitive behavior therapy.

In a clinical trial, roluperidone reduces the level of centrality associated with avolition for schizophrenia patients.

PDUFA target action date set for November 15, 2020 for the new combination olanzapine/samidorphan treatment.

In a nationwide cohort, clozapine shows the most mortality outcome benefit among schizophrenia antipsychotics.

New data shows that SEP-363856 curtails most of the debilitating side effects linked to current schizophrenia drugs.

In a new study, investigators found that 40 mg and 60 mg lumateperone is clinically safe to treat schizophrenia.

By screening during primary care visits, patients are now more aware than ever about their possibility of depression and other mental health disorders.

Lumateperone (Caplyta), a novel therapy, has received approval from the US FDA for the treatment of schizophrenia in adults.

Having a dog or cat in the first 12 years of a child's life could reduce the risk of serious psychiatric disorders later on.

How can clinicians and policy makers collaborate to improve the standing of mental health in the US?